(1 )Lauri E. Markowitz Morbidity and Mortality weekly report, Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (proposed) . “Quadrivalent Human Papillomavirus”(2007) asserts that the epidemiology of HPV and associated diseases, describes the licensed HPV vaccine, and provides recommendations for its use for vaccination among females aged 9–26 years in the United States. (2) Markowitz provides evidence that clinical trials indicate that the vaccine is safe and immunogenic. Trials among females aged 16–26 years indicated the vaccine to be effective against HPV types 6-, 11-, 16-, and 18-related cervical, vaginal and vulvar cancer precursor and dysplastic lesions, and genital warts. HPV 16 and 18 are the cause of approximately 70% of cervical cancers. (3) The purpose of this report was to provide recommendations to immune practices.(4) Markowitz establishes a tone that is intended for medical professionals and then relatable to the patients and public at large.
